GARRIGUES ADVISES KEENSIGHT CAPITAL ON 3P BIOPHARMACEUTICALS DEAL

Posted on 02/08/2019



Category: Archive





Garrigues advised Keensight Capital on the acquisition of 3P Biopharmaceuticals.



Keensight Capital - a 'growth buyout' investor that specialises in the IT and healthcare sectors - acquired a majority stake from Infarco.

3P Biopharmaceuticals specialises in the development and manufacture of medicines. The company has around 240 employees.	